|
π
|
Genetic Variation in Metabolizing Enzyme and Transporter Genes: Comprehensive Assessment in 3 Major East Asian Subpopulations With Comparison to Caucasians and Africans
11 auth.
M. Man,
M. Farmen,
C. Dumaual,
C. Teng,
B. Moser,
S. Irie,
...
G. Noh,
R. Njau,
S. Close,
S. Wise,
R. Hockett
|
7 |
2010 |
7
π
|
|
π
|
Anti-TGF-Ξ²1 Antibody Therapy in Patients with Diabetic Nephropathy.
12 auth.
J. Voelker,
P. H. Berg,
M. Sheetz,
K. Duffin,
T. Shen,
B. Moser,
...
T. Greene,
S. Blumenthal,
I. RychlΓk,
Y. Yagil,
P. Zaoui,
J. Lewis
|
7 |
2017 |
7
π
|
|
π
|
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease.
13 auth.
D. Angiolillo,
J. Jakubowski,
J. Ferreiro,
A. Tello-Montoliu,
F. Rollini,
Francesco Franchi,
Masafumi Ueno,
Andrew Darlington,
Bhaloo Desai,
B. Moser,
...
A. Sugidachi,
Luis A. GuzmΓ‘n,
T. Bass
|
7 |
2014 |
7
π
|
|
π
|
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
16 auth.
D. Erlinge,
P. Gurbel,
S. James,
T. Lindahl,
P. Svensson,
J. T. ten Berg,
D. Foley,
H. Wagner,
Patricia B. Brown,
Junxiang Luo,
...
Chunmei Zhou,
B. Moser,
J. Jakubowski,
D. Small,
K. Winters,
D. Angiolillo
|
6 |
2013 |
6
π
|
|
π
|
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
14 auth.
D. Erlinge,
J. T. ten Berg,
D. Foley,
D. Angiolillo,
H. Wagner,
Patricia B. Brown,
Chunmei Zhou,
Junxiang Luo,
J. Jakubowski,
B. Moser,
...
D. Small,
T. Bergmeijer,
S. James,
K. Winters
|
6 |
2012 |
6
π
|
|
π
|
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
11 auth.
L. Rosen,
J. Goldman,
A. Algazi,
P. K. Turner,
B. Moser,
Tianle Hu,
...
Xuejing Wang,
J. Tuttle,
V. Wacheck,
J. Wooldridge,
M. Banck
|
5 |
2016 |
5
π
|
|
π
|
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
16 auth.
A. He,
R. Cohen,
C. Denlinger,
A. Sama,
A. Birnbaum,
Jimmy J. Hwang,
Takami Sato,
N. Lewis,
M. Mynderse,
Michele Niland,
...
J. Giles,
J. Wallin,
B. Moser,
Wei Zhang,
R. Walgren,
E. Plimack
|
5 |
2019 |
5
π
|
|
π
|
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
25 auth.
J. Valle,
A. Vogel,
C. Denlinger,
A. He,
L. Bai,
R. Orlova,
E. Van Cutsem,
J. Adeva,
LiβTzong Chen,
R. Obermannova,
T. Ettrich,
JenβShi Chen,
H. Wasan,
A. Girvan,
Wei Zhang,
...
Jiangang Liu,
Chunlao Tang,
P. Ebert,
A. Aggarwal,
S. Mcneely,
B. Moser,
Joana M. Oliveira,
R. Carlesi,
R. Walgren,
D. Oh
|
5 |
2021 |
5
π
|
|
π
|
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease
17 auth.
P. Gurbel,
T. Bergmeijer,
U. Tantry,
J. T. ten Berg,
D. Angiolillo,
S. James,
T. Lindahl,
P. Svensson,
Joe T Jakubowski,
Patricia B. Brown,
...
S. Duvvuru,
S. Sundseth,
Joseph C. Walker,
D. Small,
B. Moser,
K. Winters,
D. Erlinge
|
4 |
2014 |
4
π
|
